RxDoctor Payments Data

Timothy Cornitius, MD

Dermatology · Dodge City, KSNPI 1679554133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 31.8% of the total. Reporting peaked in 2020 at $389 and has fallen 56.9% since, to $167 in 2024. That places this record below the midpoint for dermatology clinicians in KS, where the typical reported total is $1,741.

$1,427in general payments, 2019–2025

Across 79 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$454
  • Amgen$241
  • Lilly USA, LLC$190
  • Johnson & Johnson$176
  • Sun Pharmaceutical Industries Inc.$93
  • Sanofi-aventis U.S. LLC$72
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$1,35595%
  • Education$725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,427 in reported general payments places this provider in the 45th percentile of 82 dermatology providers in Kansas.

See all dermatology providers in Kansas

Medicare billing

Part B allowed, 2024
$81,556
Medicare patients
381
Services billed
1,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx (2 Syringes)Secukinumab13$98,761
Clobetasol Propionate26$3,378
Methoxsalen11$2,751
Fluorouracil14$1,284
Minocycline Hcl16$622
Triamcinolone Acetonide54$533
ValacyclovirValacyclovir Hcl22$333
Imiquimod16$291
MethotrexateMethotrexate Sodium14$105
Hydroxyzine Hcl11$56
Acyclovir13$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$56$98,76113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 82 dermatology providers in Kansas.

Other dermatology in Dodge City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →